The global peripheral vascular devices market is expected to enjoy a valuation of US$ 4.7 Billion by the end of the year 2022, and further expand at a CAGR of 6.6% to reach a valuation of US$ 8.9 Billion by the year 2032. According to a recent study by Future Market Insights, peripheral vascular stents are leading the market with a share of about 78.5% in the year 2021, within the global market.
Market Outlook:
Data Points | Market Insights |
---|---|
Market Value 2021 | US$ 4.5 Billion |
Market Value 2022 | US$ 4.7 Billion |
Market Value 2032 | US$ 8.9 Billion |
CAGR 2022 to 2032 | 6.6% |
Market Share of Top 5 Countries | 57.6% |
Key Market Players | Abbott Laboratories, Boston Scientific Corporation, Cook Medical Inc., MicroPort Scientific Corporation (Endovastec™), Medtronic Plc., Cardinal Health, Inc., B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Becton, Dickinson and Company, W. L. Gore & Associates Inc., Getinge AB, Terumo Corp, Kyoto Medical Planning Co Ltd, iVascular S.L.U, AMG International GmbH, ENDOCOR GmbH, Meril Life Sciences Pvt. Ltd., Nano Therapeutics Pvt Ltd, Koninklijke Philips N.V., and REVA Medical |
Plaque in the arteries that carry blood to the body is the primary cause of peripheral arterial disease (PAD). It generally suggests systemic atherosclerosis and an elevated risk of cardiovascular events. Diabetic patients, smokers, the elderly, and those with cardiovascular disease are most vulnerable to PAD. About half of the persons with PAD are asymptomatic, regardless of whether it causes symptoms, PAD can imply systemic atherosclerosis and an elevated risk of heart disease and stroke. Many novel technologies, as well as new versions of existing devices, are now available for endovascular, less invasive treatment of PAD.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for peripheral vascular devices was approximately 52.0% of the overall US$ 8.6 Billion of the global stents market in 2021.
The sales of peripheral vascular devices expanded at a CAGR of 4.4% from 2012 to 2021, owing to a high incidence of cardiovascular disease burden, globally.
Minimally invasive endovascular procedures to expand the artery opening, such as angioplasty or atherectomy, are currently employed more frequently than bypass surgery as the initial treatment strategy for PAD. The two primary forms of endovascular therapies for PAD are balloon angioplasty with stenting and atherectomy. Endovascular therapy or vascular surgery can be used to treat patients with severe PAD.
A large volume of the population worldwide suffers from critical limb ischemia (CLI), the most severe form of peripheral arterial disease (PAD). While endovascular therapy has been the first choice of treatment in the majority of cases, there is still a range of barriers to the best treatment of diseases such as infrapopliteal (IP) disease.
Endovascular therapy outcomes have significantly improved as technology has advanced. Several innovative technologies are now being developed, including intravascular lithotripsy, percutaneous femoropopliteal bypass, paclitaxel-eluting stents, and the adventitial delivery of anti-restenosis medicines.
As the world's population has grown, so has the demand for healthcare services. Due to an increase in the senior population, the number of individuals suffering from cardiovascular disorders has continually increased. As a result, the demand for devices used in the treatment of cardiovascular disorders has increased. Peripheral vascular devices can be used to treat a variety of heart and arterial problems.
Additionally, technological developments have had a favorable impact on the market shares for peripheral vascular devices. Moreover, the rapid growth of the healthcare industry in developing nations has a beneficial impact on the peripheral vascular devices market growth.
Thus, owing to the aforementioned factors, the global peripheral vascular devices market is expected to grow at a CAGR of 6.6% during the forecast period from 2022 to 2032.
The market for peripheral vascular devices is set to be presented with opportunistic growth over the forecast period. This growth is expected to be owed to the introduction of novel products, such as upgraded drug-eluting vascular stents.
The FDA granted Boston Scientific an investigational device exemption (IDE) in 2015 to initiate a global, pivotal study of the Eluvia drug-eluting stent. EluviaTM Drug-Eluting Vascular Stent System was designed exclusively for the treatment of peripheral artery disease, and in 2018, the USA Food and Drug Administration (FDA) authorized its Premarket Approval (PMA) application.
Stents were first created as a tube that could be inserted intraluminally out of a metal alloy. Bare metal stents (BMSs), coated stents, and drug-eluting stents (DESs) are all types of stents that have evolved in recent years. They may also be self-expanding and balloon expandable. Stents are currently mostly made of nickel and titanium, stainless steel, cobalt chromium, or nickel and titanium.
Biodegradable polymers have been used to create bioabsorbable stents. Although the concept of a bioabsorbable material holds promise, it has not been established in randomized controlled studies and has not demonstrated enhanced or equivalent patency when compared to endarterectomy and PTA.
With the research and development required to improve the outcomes over more standardized approaches, the key players are presented with lucrative prospects for advancement.
The growth of the peripheral vascular devices market is restricted by factors that include device recall activities, device limitations, and the high cost of advanced devices. Medtronic issued the FDA’s most serious type of medical device recall, Class I, in response to reports of injuries associated with its HawkOne system for clearing blocked arteries. About 95,000 devices sold to the United States of America since 2018 were subject to the recall, which Medtronic announced in early December 2021. Moreover, the material cost composition of peripheral vascular devices is greater within institutional settings, and the high-cost burden of adoption of these devices is a factor, which hinders the overall market.
Additionally, device limitations during the surgical procedure further pose a restrictive impact on the market expansion. Several procedures utilizing drug-eluting balloons come with the risk of occurrence of restenosis after treatment.
Keeping the above factors into consideration, the global market for peripheral vascular stents is subject to repression, in terms of growth, over the forecast period.
The USA dominates the North American region with a total market share of about 94.5% in 2021 and is expected to continue to experience the same growth throughout the forecast period. With a large population suffering from cardiovascular disorders, the product adoption rate for peripheral vascular devices is quite high within the country, thus propelling the USA into being the largest contributor towards the growth of the global peripheral vascular stents market.
China holds approximately 56.5% share of the East Asia market in 2021 and is projected to display growth at a lucrative CAGR of 8.5% during the forecast period. China presents lucrative prospects for the growth of the overall market, owing to a prospective, multicenter, randomized, and controlled, superiority trial done at 14 hospitals in China as part of the FREEWAY-CHINA project.
The objective of this study was to assess the effectiveness and safety of the FREEWAY paclitaxel-coated balloon. According to the study, the FREEWAY paclitaxel-coated balloon outperformed the uncoated balloon in Chinese patients' target lesion revascularization at the 6- and 12-month mark. With established device adaptability and efficacy in the demographic, the market is poised to be fuelled by future product adoption within the country.
Germany is set to exhibit a CAGR of nearly 6.0% in the European peripheral vascular devices market during the forecast period. The market expansion in Germany is owed to the large geriatric population, advanced medical device technology and research, and a high prevalence of chronic diseases.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Peripheral vascular stents are expected to present high growth at a CAGR of 6.0% by the end of the forecast period. With angioplasty procedures, the use of peripheral vascular stents is adapted for implantation into the artery for the removal of calcified lesions. A large disease population globally calls for a greater number of procedures involving the adoption of peripheral vascular stents, thus promoting this segment’s overall market value.
Peripheral arterial disease holds a revenue share of 30.3% in the global market in 2021. Growing urban lifestyle, as well as a large population consuming alcohol and tobacco, are factors propelling the development of peripheral arterial disease. This segment thus holds a major focus within the market.
iliac artery holds a global revenue share of around 48.1% in 2021. Claudication and/or critical limb ischemia are primarily caused by aortoiliac disease, which has a prevalence of up to 10% in the general population and up to 20% in people over the age of 70 (Annals of Vascular Surgery, 2017). Peripheral artery disease includes aortoiliac occlusive disease.
A substantial portion of the global market for peripheral vascular devices is focused on the iliac artery segment due to increased concerns about this condition.
Hospitals hold the highest market share of about 60.4% during the year 2021. The growing prevalence of chronic and infectious diseases, as well as the associated increasing volumes of surgical procedures, have driven this segment to be a dominant fragment, propelling sales of the overall peripheral vascular devices market.
The overall market is highly fragmented, with multiple rivals in the peripheral vascular device production sphere. These companies are using techniques such as mergers and acquisitions, partnerships and collaborations, and new product releases to meet consumer demand and expand their customer base.
Similarly, recent developments related to companies manufacturing peripheral vascular devices, have been tracked by the team at Future Market Insights, which are available in the full report.
Attribute | Details |
---|---|
Forecast Period | 2012 to 2021 |
Historical Data Available for | 2022 to 2032 |
Market Analysis | US$ Million for Value |
Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Nordic countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, Israel, North Africa, and South Africa |
Key Market Segments Covered | Product, Indication, Artery, End User, and Region |
Key Companies Profiled |
|
Pricing | Available upon Request |
The global peripheral vascular devices market is worth US$ 4.5 Billion in 2021 and is set to expand 1.9X over the next ten years.
The peripheral vascular devices market is expected to reach US$ 8.9 Billion by the end of 2032, with sales revenue expected to register 6.6% CAGR.
The growing burden of cardiovascular diseases, rising awareness regarding cardiovascular procedures, and the adoption of minimally invasive surgical techniques are some of the key trends in this market.
The USA, China, Germany, the United Kingdom, and India are expected to drive demand for the peripheral vascular devices industry.
Demand for peripheral vascular devices in South Asia is expected to register a 7.1% CAGR over the next ten years.
North America is one of the key markets for peripheral vascular devices, with the USA accounting for about 94.5% of the North American peripheral vascular devices market in the year 2021.
Demand for peripheral vascular devices in Europe is expected to register a 6.2% CAGR over the next ten years.
The USA, China, and Germany are the key producers of peripheral vascular devices.
Demand for peripheral vascular devices in the Middle East and Africa(MEA) is expected to register a 5.7% CAGR over the next ten years.
Abbott Laboratories, Boston Scientific Corporation, Cook Medical Inc., MicroPort Scientific Corporation (Endovastec™), Medtronic Plc., Cardinal Health, Inc., B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Becton, Dickinson and Company, W. L. Gore & Associates Inc., Getinge AB, Terumo Corp, Kyoto Medical Planning Co Ltd, iVascular S.L.U, AMG International GmbH, ENDOCOR GmbH, Meril Life Sciences Pvt. Ltd., Nano Therapeutics Pvt Ltd, Koninklijke Philips N.V., and REVA Medical, are some of the key pl
1. Executive Summary | Peripheral Vascular Devices Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Product Adoption / Usage Analysis 4.2. Product USP Analysis 4.3. Key Strategies adopted by manufacturers 4.4. Regulatory Scenario 4.5. Technology Assessment 4.6. Value Chain Analysis 4.7. Recent Product Launches 4.8. PESTLE Analysis 4.9. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Spending Outlook 5.1.3. Global Stent Market Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rising Number of Peripheral Surgeries 5.2.2. Technological Advancements 5.2.3. Regulatory Landscape 5.2.4. Cost of Procedures 5.2.5. Product Adoption Rate and Demand 5.2.6. Increase in Research and Development 5.2.7. Pharmaceutical Industry Consolidation Activities 5.2.8. Top Companies’ Historical Growth 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. By Product 6.1.2. By Indication 6.1.3. By Artery 6.1.4. By End User 6.1.5. By Region 6.2. 2021 Market Scenario 7. Global Market Volume (Thousands) Analysis 2012 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Volume (Thousands) Analysis, 2012 to 2021 7.2. Current and Future Market Volume (Thousands) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 8. Global Market - Pricing Analysis 8.1. Regional Pricing Analysis By Product 8.2. Pricing Break Up 8.2.1. Manufacturer Level 8.2.2. Distributor Level 8.3. Global Average Pricing Analysis Benchmark 8.4. Pricing Assumptions 9. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032 9.1. Historical Market Value (US$ Million) Analysis 2012 to 2021 9.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 9.2.1. Y-o-Y Growth Trend Analysis 9.2.2. Absolute $ Opportunity Analysis 10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Product 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Product, 2012 to 2021 10.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Product, 2022 to 2032 10.3.1. Peripheral Vascular Stents 10.3.1.1. Self-Expanding Stents 10.3.1.2. Balloon Expanding Stents 10.3.1.3. Covered Stents 10.3.1.4. Drug Eluting Stents 10.3.2. Drug Eluting Balloons 10.3.3. Peripheral Vascular Bioresorbable Scaffolds 10.4. Market Attractiveness Analysis By Product 11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Indication, 2012 to 2021 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2022 to 2032 11.3.1. Target Artery Instability (TAI) 11.3.2. Access Artery Injury (AAI) 11.3.3. Peripheral Arterial Disease 11.3.4. Arteriovenous Fistulas 11.3.5. Peripheral Aneurysms 11.3.6. Others 11.4. Market Attractiveness Analysis By Indication 12. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Artery 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis By Artery, 2012 to 2021 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Artery, 2022 to 2032 12.3.1. Carotid Artery 12.3.2. Fem-Pop Artery 12.3.3. Iliac Artery 12.3.4. Infrapop Artery 12.4. Market Attractiveness Analysis By Artery 13. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis By End User, 2012 to 2021 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2022 to 2032 13.3.1. Hospitals 13.3.2. Ambulatory Surgical Centers/Outpatients 13.3.3. Cardiac Catheterization Labs 13.4. Market Attractiveness Analysis By End User 14. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region 14.1. Introduction 14.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Region, 2012 to 2021 14.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Region, 2022 to 2032 14.3.1. North America 14.3.2. Latin America 14.3.3. Europe 14.3.4. South Asia 14.3.5. East Asia 14.3.6. Oceania 14.3.7. Middle East & Africa (MEA) 14.4. Market Attractiveness Analysis By Region 15. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 15.1. Introduction / Key Findings 15.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Region, 2012 to 2021 15.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Region, 2022 to 2032 15.3.1. By Country 15.3.1.1. USA 15.3.1.2. Canada 15.3.2. By Product 15.3.3. By Indication 15.3.4. By Artery 15.3.5. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Product 15.4.2. By Indication 15.4.3. By Artery 15.4.4. By End User 15.4.5. By Country 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country-Level Analysis & Forecast 15.8.1. USA Market 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Product 15.8.1.2.2. By Indication 15.8.1.2.3. By Artery 15.8.1.2.4. By End User 15.8.2. Canada Market 15.8.3. Introduction 15.8.4. Market Analysis and Forecast by Market Taxonomy 15.8.4.1.1. By Product 15.8.4.1.2. By Indication 15.8.4.1.3. By Artery 15.8.4.1.4. By End User 16. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Market Taxonomy, 2012 to 2021 16.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Market Taxonomy, 2022 to 2032 16.3.1. By Country 16.3.1.1. Brazil 16.3.1.2. Mexico 16.3.1.3. Argentina 16.3.1.4. Rest of Latin America 16.3.2. By Product 16.3.3. By Indication 16.3.4. By Artery 16.3.5. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Product 16.4.2. By Indication 16.4.3. By Artery 16.4.4. By End User 16.4.5. By Country 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country-Level Analysis & Forecast 16.8.1. Brazil Market 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Product 16.8.1.2.2. By Indication 16.8.1.2.3. By Artery 16.8.1.2.4. By End User 16.8.2. Mexico Market 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Product 16.8.2.2.2. By Indication 16.8.2.2.3. By Artery 16.8.2.2.4. By End User 16.8.3. Argentina Market 16.8.4. Introduction 16.8.5. Market Analysis and Forecast by Market Taxonomy 16.8.5.1. By Product 16.8.5.2. By Indication 16.8.5.3. By Artery 16.8.5.4. By End User 17. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032 17.1. Introduction 17.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Market Taxonomy, 2012 to 2021 17.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Market Taxonomy, 2022 to 2032 17.3.1. By Country 17.3.1.1. Germany 17.3.1.2. Italy 17.3.1.3. France 17.3.1.4. United Kingdom 17.3.1.5. Spain 17.3.1.6. BENELUX 17.3.1.7. Russia 17.3.1.8. Nordic Countries 17.3.1.9. Rest of Europe 17.3.2. By Product 17.3.3. By Indication 17.3.4. By Artery 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Product 17.4.2. By Indication 17.4.3. By Artery 17.4.4. By End User 17.4.5. By Country 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country-Level Analysis & Forecast 17.8.1. Germany Market 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Product 17.8.1.2.2. By Indication 17.8.1.2.3. By Artery 17.8.1.2.4. By End User 17.8.2. Italy Market 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Product 17.8.2.2.2. By Indication 17.8.2.2.3. By Artery 17.8.2.2.4. By End User 17.8.3. France Market 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Product 17.8.3.2.2. By Indication 17.8.3.2.3. By Artery 17.8.3.2.4. By End User 17.8.4. United Kingdom Market 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast by Market Taxonomy 17.8.4.2.1. By Product 17.8.4.2.2. By Indication 17.8.4.2.3. By Artery 17.8.4.2.4. By End User 17.8.5. Spain Market 17.8.5.1. Introduction 17.8.5.2. Market Analysis and Forecast by Market Taxonomy 17.8.5.2.1. By Product 17.8.5.2.2. By Indication 17.8.5.2.3. By Artery 17.8.5.2.4. By End User 17.8.6. BENELUX Market 17.8.6.1. Introduction 17.8.6.2. Market Analysis and Forecast by Market Taxonomy 17.8.6.2.1. By Product 17.8.6.2.2. By Indication 17.8.6.2.3. By Artery 17.8.6.2.4. By End User 17.8.7. Russia Market 17.8.7.1. Introduction 17.8.7.2. Market Analysis and Forecast by Market Taxonomy 17.8.7.2.1. By Product 17.8.7.2.2. By Indication 17.8.7.2.3. By Artery 17.8.7.2.4. By End User 17.8.8. Nordic Countries Market 17.8.8.1. Introduction 17.8.8.2. Market Analysis and Forecast by Market Taxonomy 17.8.8.2.1. By Product 17.8.8.2.2. By Indication 17.8.8.2.3. By Artery 17.8.8.2.4. By End User 18. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 18.1. Introduction 18.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Market Taxonomy, 2012 to 2021 18.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Market Taxonomy, 2022 to 2032 18.3.1. By Country 18.3.1.1. China 18.3.1.2. Japan 18.3.1.3. South Korea 18.3.2. By Product 18.3.3. By Indication 18.3.4. By Artery 18.3.5. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Product 18.4.2. By Indication 18.4.3. By Artery 18.4.4. By End User 18.4.5. By Country 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country-Level Analysis & Forecast 18.8.1. China Market 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Product 18.8.1.2.2. By Indication 18.8.1.2.3. By Artery 18.8.1.2.4. By End User 18.8.2. Japan Market 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Product 18.8.2.2.2. By Indication 18.8.2.2.3. By Artery 18.8.2.2.4. By End User 18.8.3. South Korea Market 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Product 18.8.3.2.2. By Indication 18.8.3.2.3. By Artery 18.8.3.2.4. By End User 19. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 19.1. Introduction 19.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Market Taxonomy, 2012 to 2021 19.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Market Taxonomy, 2022 to 2032 19.3.1. By Country 19.3.1.1. India 19.3.1.2. Indonesia 19.3.1.3. Malaysia 19.3.1.4. Thailand 19.3.1.5. Rest of South Asia 19.3.2. By Product 19.3.3. By Indication 19.3.4. By Artery 19.3.5. By End User 19.4. Market Attractiveness Analysis 19.4.1. By Product 19.4.2. By Indication 19.4.3. By Artery 19.4.4. By End User 19.4.5. By Country 19.5. Market Trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country-Level Analysis & Forecast 19.8.1. India Market 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Product 19.8.1.2.2. By Indication 19.8.1.2.3. By Artery 19.8.1.2.4. By End User 19.8.2. Indonesia Market 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Product 19.8.2.2.2. By Indication 19.8.2.2.3. By Artery 19.8.2.2.4. By End User 19.8.3. Malaysia Market 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Product 19.8.3.2.2. By Indication 19.8.3.2.3. By Artery 19.8.3.2.4. By End User 19.8.4. Thailand Market 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast by Market Taxonomy 19.8.4.2.1. By Product 19.8.4.2.2. By Indication 19.8.4.2.3. By Artery 19.8.4.2.4. By End User 20. Oceania Market Analysis 2012 to 2021 and Forecast 2022 to 2032 20.1. Introduction 20.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Market Taxonomy, 2012 to 2021 20.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Market Taxonomy, 2022 to 2032 20.3.1. By Country 20.3.1.1. Australia 20.3.1.2. New Zealand 20.3.2. By Product 20.3.3. By Indication 20.3.4. By Artery 20.3.5. By End User 20.4. Market Attractiveness Analysis 20.4.1. By Product 20.4.2. By Indication 20.4.3. By Artery 20.4.4. By End User 20.4.5. By Country 20.5. Market Trends 20.6. Key Market Participants - Intensity Mapping 20.7. Drivers and Restraints - Impact Analysis 20.8. Country-Level Analysis & Forecast 20.8.1. Australia Market 20.8.1.1. Introduction 20.8.1.2. Market Analysis and Forecast by Market Taxonomy 20.8.1.2.1. By Product 20.8.1.2.2. By Indication 20.8.1.2.3. By Artery 20.8.1.2.4. By End User 20.8.2. New Zealand Market 20.8.2.1. Introduction 20.8.2.2. Market Analysis and Forecast by Market Taxonomy 20.8.2.2.1. By Product 20.8.2.2.2. By Indication 20.8.2.2.3. By Artery 20.8.2.2.4. By End User 21. Middle East and Africa Market Analysis 2012 to 2021 and Forecast 2022 to 2032 21.1. Introduction 21.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Market Taxonomy, 2012 to 2021 21.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Market Taxonomy, 2022 to 2032 21.3.1. By Country 21.3.1.1. GCC Countries 21.3.1.2. Turkey 21.3.1.3. Israel 21.3.1.4. North Africa 21.3.1.5. South Africa 21.3.1.6. Rest of Middle East and Africa 21.3.2. By Product 21.3.3. By Indication 21.3.4. By Artery 21.3.5. By End User 21.4. Market Attractiveness Analysis 21.4.1. By Product 21.4.2. By Indication 21.4.3. By Artery 21.4.4. By End User 21.4.5. By Country 21.5. Market Trends 21.6. Key Market Participants - Intensity Mapping 21.7. Drivers and Restraints - Impact Analysis 21.8. Country-Level Analysis & Forecast 21.8.1. GCC Countries Market 21.8.1.1. Introduction 21.8.1.2. Market Analysis and Forecast by Market Taxonomy 21.8.1.2.1. By Product 21.8.1.2.2. By Indication 21.8.1.2.3. By Artery 21.8.1.2.4. By End User 21.8.2. Turkey Market 21.8.2.1. Introduction 21.8.2.2. Market Analysis and Forecast by Market Taxonomy 21.8.2.2.1. By Product 21.8.2.2.2. By Indication 21.8.2.2.3. By Artery 21.8.2.2.4. By End User 21.8.3. Israel Market 21.8.3.1. Introduction 21.8.3.2. Market Analysis and Forecast by Market Taxonomy 21.8.3.2.1. By Product 21.8.3.2.2. By Indication 21.8.3.2.3. By Artery 21.8.3.2.4. By End User 21.8.4. North Africa Market 21.8.4.1. Introduction 21.8.4.2. Market Analysis and Forecast by Market Taxonomy 21.8.4.2.1. By Product 21.8.4.2.2. By Indication 21.8.4.2.3. By Artery 21.8.4.2.4. By End User 21.8.5. South Africa Market 21.8.5.1. Introduction 21.8.5.2. Market Analysis and Forecast by Market Taxonomy 21.8.5.2.1. By Product 21.8.5.2.2. By Indication 21.8.5.2.3. By Artery 21.8.5.2.4. By End User 22. Market Structure Analysis 22.1. Market Analysis by Tier of Companies 22.2. Market Share Analysis (%) of Top Players 22.3. Market Presence Analysis 22.3.1. Regional Footprint by Players 22.3.2. Product Footprint by Players 22.3.3. Channel Foot Print by Players 23. Competition Analysis 23.1. Competition Dashboard 23.2. Competition Benchmarking 23.3. Competition Deep Dive 23.3.1. Abbott Laboratories 23.3.1.1. Overview 23.3.1.2. Product Portfolio 23.3.1.3. Sales Footprint 23.3.1.4. Key Financials 23.3.1.5. SWOT Analysis 23.3.1.6. Strategy Overview 23.3.1.6.1. Marketing Strategy 23.3.1.6.2. Product Strategy 23.3.1.6.3. Channel Strategy 23.3.2. Boston Scientific Corporation 23.3.2.1. Overview 23.3.2.2. Product Portfolio 23.3.2.3. Sales Footprint 23.3.2.4. Key Financials 23.3.2.5. SWOT Analysis 23.3.2.6. Strategy Overview 23.3.2.6.1. Marketing Strategy 23.3.2.6.2. Product Strategy 23.3.2.6.3. Channel Strategy 23.3.3. Cook Medical Inc. 23.3.3.1. Overview 23.3.3.2. Product Portfolio 23.3.3.3. Sales Footprint 23.3.3.4. Key Financials 23.3.3.5. SWOT Analysis 23.3.3.6. Strategy Overview 23.3.3.6.1. Marketing Strategy 23.3.3.6.2. Product Strategy 23.3.3.6.3. Channel Strategy 23.3.4. MicroPort Scientific Corporation (Endovastec™) 23.3.4.1. Overview 23.3.4.2. Product Portfolio 23.3.4.3. Sales Footprint 23.3.4.4. Key Financials 23.3.4.5. SWOT Analysis 23.3.4.6. Strategy Overview 23.3.4.6.1. Marketing Strategy 23.3.4.6.2. Product Strategy 23.3.4.6.3. Channel Strategy 23.3.5. Medtronic Plc. 23.3.5.1. Overview 23.3.5.2. Product Portfolio 23.3.5.3. Sales Footprint 23.3.5.4. Key Financials 23.3.5.5. SWOT Analysis 23.3.5.6. Strategy Overview 23.3.5.6.1. Marketing Strategy 23.3.5.6.2. Product Strategy 23.3.5.6.3. Channel Strategy 23.3.6. Cardinal Health, Inc. 23.3.6.1. Overview 23.3.6.2. Product Portfolio 23.3.6.3. Sales Footprint 23.3.6.4. Key Financials 23.3.6.5. SWOT Analysis 23.3.6.6. Strategy Overview 23.3.6.6.1. Marketing Strategy 23.3.6.6.2. Product Strategy 23.3.6.6.3. Channel Strategy 23.3.7. B. Braun Melsungen AG 23.3.7.1. Overview 23.3.7.2. Product Portfolio 23.3.7.3. Sales Footprint 23.3.7.4. Key Financials 23.3.7.5. SWOT Analysis 23.3.7.6. Strategy Overview 23.3.7.6.1. Marketing Strategy 23.3.7.6.2. Product Strategy 23.3.7.6.3. Channel Strategy 23.3.8. BIOTRONIK SE & Co. KG 23.3.8.1. Overview 23.3.8.2. Product Portfolio 23.3.8.3. Sales Footprint 23.3.8.4. Key Financials 23.3.8.5. SWOT Analysis 23.3.8.6. Strategy Overview 23.3.8.6.1. Marketing Strategy 23.3.8.6.2. Product Strategy 23.3.8.6.3. Channel Strategy 23.3.9. Becton, Dickinson, and Company 23.3.9.1. Overview 23.3.9.2. Product Portfolio 23.3.9.3. Sales Footprint 23.3.9.4. Key Financials 23.3.9.5. SWOT Analysis 23.3.9.6. Strategy Overview 23.3.9.6.1. Marketing Strategy 23.3.9.6.2. Product Strategy 23.3.9.6.3. Channel Strategy 23.3.10. W. L. Gore & Associates Inc. 23.3.10.1. Overview 23.3.10.2. Product Portfolio 23.3.10.3. Sales Footprint 23.3.10.4. Key Financials 23.3.10.5. SWOT Analysis 23.3.10.6. Strategy Overview 23.3.10.6.1. Marketing Strategy 23.3.10.6.2. Product Strategy 23.3.10.6.3. Channel Strategy 23.3.11. Getinge AB 23.3.11.1. Overview 23.3.11.2. Product Portfolio 23.3.11.3. Sales Footprint 23.3.11.4. Key Financials 23.3.11.5. SWOT Analysis 23.3.11.6. Strategy Overview 23.3.11.6.1. Marketing Strategy 23.3.11.6.2. Product Strategy 23.3.11.6.3. Channel Strategy 23.3.12. Terumo Corp 23.3.12.1. Overview 23.3.12.2. Product Portfolio 23.3.12.3. Sales Footprint 23.3.12.4. Key Financials 23.3.12.5. SWOT Analysis 23.3.12.6. Strategy Overview 23.3.12.6.1. Marketing Strategy 23.3.12.6.2. Product Strategy 23.3.12.6.3. Channel Strategy 23.3.13. Kyoto Medical Planning Co Ltd 23.3.13.1. Overview 23.3.13.2. Product Portfolio 23.3.13.3. Sales Footprint 23.3.13.4. Key Financials 23.3.13.5. SWOT Analysis 23.3.13.6. Strategy Overview 23.3.13.6.1. Marketing Strategy 23.3.13.6.2. Product Strategy 23.3.13.6.3. Channel Strategy 23.3.14. iVascular S.L.U 23.3.14.1. Overview 23.3.14.2. Product Portfolio 23.3.14.3. Sales Footprint 23.3.14.4. Key Financials 23.3.14.5. SWOT Analysis 23.3.14.6. Strategy Overview 23.3.14.6.1. Marketing Strategy 23.3.14.6.2. Product Strategy 23.3.14.6.3. Channel Strategy 23.3.15. AMG International GmbH 23.3.15.1. Overview 23.3.15.2. Product Portfolio 23.3.15.3. Sales Footprint 23.3.15.4. Key Financials 23.3.15.5. SWOT Analysis 23.3.15.6. Strategy Overview 23.3.15.6.1. Marketing Strategy 23.3.15.6.2. Product Strategy 23.3.15.6.3. Channel Strategy 23.3.16. ENDOCOR GmbH 23.3.16.1. Overview 23.3.16.2. Product Portfolio 23.3.16.3. Sales Footprint 23.3.16.4. Key Financials 23.3.16.5. SWOT Analysis 23.3.16.6. Strategy Overview 23.3.16.6.1. Marketing Strategy 23.3.16.6.2. Product Strategy 23.3.16.6.3. Channel Strategy 23.3.17. Meril Life Sciences Pvt. Ltd. 23.3.17.1. Overview 23.3.17.2. Product Portfolio 23.3.17.3. Sales Footprint 23.3.17.4. Key Financials 23.3.17.5. SWOT Analysis 23.3.17.6. Strategy Overview 23.3.17.6.1. Marketing Strategy 23.3.17.6.2. Product Strategy 23.3.17.6.3. Channel Strategy 23.3.18. Nano Therapeutics Pvt Ltd 23.3.18.1. Overview 23.3.18.2. Product Portfolio 23.3.18.3. Sales Footprint 23.3.18.4. Key Financials 23.3.18.5. SWOT Analysis 23.3.18.6. Strategy Overview 23.3.18.6.1. Marketing Strategy 23.3.18.6.2. Product Strategy 23.3.18.6.3. Channel Strategy 23.3.19. Koninklijke Philips N.V. 23.3.19.1. Overview 23.3.19.2. Product Portfolio 23.3.19.3. Sales Footprint 23.3.19.4. Key Financials 23.3.19.5. SWOT Analysis 23.3.19.6. Strategy Overview 23.3.19.6.1. Marketing Strategy 23.3.19.6.2. Product Strategy 23.3.19.6.3. Channel Strategy 23.3.20. REVA Medical 23.3.20.1. Overview 23.3.20.2. Product Portfolio 23.3.20.3. Sales Footprint 23.3.20.4. Key Financials 23.3.20.5. SWOT Analysis 23.3.20.6. Strategy Overview 23.3.20.6.1. Marketing Strategy 23.3.20.6.2. Product Strategy 23.3.20.6.3. Channel Strategy 24. Assumptions and Acronyms Used 25. Research Methodology
Healthcare
September 2017
REP-GB-4991
August 2023
315 pages
Explore Healthcare Insights
View Reports